Lincoln Tsang
Ropes & Gray LLPLincoln Tsang heads up a team at Ropes & Gray LLP whose offering spans transactional, regulatory, litigation and enforcement matters and is praised for its ‘unsurpassed knowledge of the laws and regulations covering the pharma and biotech industries.’ Tsang frequently brings his regulatory expertise to bear on internal investigations and public policy matters concerning the life sciences industry. David Dowling is active across venture capital investments and private M&A. Hannah Kerr-Peterson further extends the regulatory expertise at the firm.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The practice excels in crafting regulatory strategies central to the preservation of exclusivity of important pharmaceutical products for key pharma clients while avoiding risks of claims by competitors of anti-competitive behavior, managing potential enforcement actions as well as product liability claims that may arise from drug safety and defending companies in promotional disputes with key competitors.’
‘Lincoln Tsang enjoys unparalleled standing and credibility in the life sciences sector based on his extensive experience both as a regulator and long-standing outside counsel to numerous bio-pharmaceutical and med tech companies. He is extremely knowledgeable and practical with the ability to handle technically complex and legally challenging mandates. His practice is supported by a team of up-and coming- next generation practitioners, notably Hannah Kerr Peterson and Daisy Bray.’
‘The team at Ropes and Gray have an unsurpassed knowledge of the laws and regulations covering the pharma and biotech industries and, more unusually, this knowledge is combined with an excellent feel for the complexities and nuances of actually running such a company. Their advice stands apart for its practicality and usability. They also combine this with being genuinely nice and easy to work with.’
‘I have worked with Lincoln Tsang since the mid-1990s; I have found him to be unfailingly diligent, knowledgeable and proactively helpful. He is also very pleasant to work with, and I return to him time and time again.’
Key clients
- Bain Capital
- NeoGenomics
- Avista Capital Partners
- Blackstone Group
- Novavax
- Pfizer
- PTC Therapeutics
- Takeda Pharmaceuticals International
- Merck KGaA
- Sarepta Therapeutics, Inc.
- Chroma Medicine, Inc.
- ConforMIS, Inc.
- Bluebird
- Orphalan (previously Gmp-Orphan)
- Horizon Therapeutics
- BioMarin
- Intrabio
- Nasus Pharma
- Mirum Pharmaceuticals
- Akebia Therapeutics, Inc.
- Spruce Biosciences
- Gyroscope Biotherapeutics
- Ipsen Biopharmaceuticals
- Kyowa Kirin Co.
- Amicus Therapeutics
- Allergan
- Actimed Therapeutics
Work highlights
- Advised Advent International and Warburg Pincus on their investment in Baxter International Inc.’s BioPharma Solutions (BPS) business. Under the terms of the definitive agreement, Baxter will receive $4.25 billion in cash, subject to certain closing adjustments.
- Successfully represented in the European Court of Human Rights of its pro bono client Šarūnas Narbutas, a lawyer and a patient advocate in Lithuania, who spoke out against the Lithuanian Government for its mismanagement of healthcare services for cancer patients during the Covid pandemic.
- Represented U.S.-headquartered biotech company Jounce Therapeutics, Inc. on its sale to Concentra Biosciences, LLC, an affiliate of Tang Capital Management, for $1.85 per share plus one contingent value right per share with respect to certain legacy assets of Jounce.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Lincoln Tsang